Paper36733367
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia.
Johanssen T and 8 others. Front Oncol, 2022. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. Papers, record 36733367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36733367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 28596 | Cancer Research UK | United Kingdom | PubMed |
Source PubMed
References212
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33199490 | Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33199490 | PubMed |
| 2 | 17051156 | Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. | Nature | 2006 | https://conductscience.org/library/papers/17051156 | PubMed |
| 3 | 25239666 | Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/25239666 | PubMed |
| 4 | 19519402 | Hypoxia and radiation therapy: past history, ongoing research, and future promise. | Curr Mol Med | 2009 | https://conductscience.org/library/papers/19519402 | PubMed |
| 5 | 23042933 | Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. | J Natl Cancer Inst | 2012 | https://conductscience.org/library/papers/23042933 | PubMed |
| 6 | 30694423 | A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia. | J Neurooncol | 2019 | https://conductscience.org/library/papers/30694423 | PubMed |
| 7 | 32012154 | SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. | PLoS Comput Biol | 2020 | https://conductscience.org/library/papers/32012154 | PubMed |
| 8 | 29196443 | Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture. | Dis Model Mech | 2018 | https://conductscience.org/library/papers/29196443 | PubMed |
| 9 | 19720927 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19720927 | PubMed |
| 10 | 25762461 | Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/25762461 | PubMed |
| 11 | 31747009 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/31747009 | PubMed |
| 12 | 22854781 | A restricted cell population propagates glioblastoma growth after chemotherapy. | Nature | 2012 | https://conductscience.org/library/papers/22854781 | PubMed |
| 13 | 16520474 | Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. | Ann Intern Med | 2006 | https://conductscience.org/library/papers/16520474 | PubMed |
| 14 | 29300332 | Role of Microenvironment in Glioma Invasion: What We Learned from In Vitro Models. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/29300332 | PubMed |
| 15 | 32154928 | NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. | Cancer | 2020 | https://conductscience.org/library/papers/32154928 | PubMed |
| 16 | 16028354 | Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. | Mol Pharm | 2004 | https://conductscience.org/library/papers/16028354 | PubMed |
| 17 | 29126203 | A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. | Neuro Oncol | 2018 | https://conductscience.org/library/papers/29126203 | PubMed |
| 18 | 32367437 | Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. | J Neurooncol | 2020 | https://conductscience.org/library/papers/32367437 | PubMed |
| 19 | 31882946 | Deep sequencing and automated histochemistry of human tissue slice cultures improve their usability as preclinical model for cancer research. | Sci Rep | 2019 | https://conductscience.org/library/papers/31882946 | PubMed |
| 20 | 32616710 | Overcoming cancer therapeutic bottleneck by drug repurposing. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/32616710 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41385182 | VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41385182 | PubMed |
| 40649933 | A New Adjuvant Treatment for Glioblastoma Using Aprepitant, Vortioxetine, Roflumilast and Olanzapine: The AVRO Regimen. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40649933 | PubMed |
| 40430842 | Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40430842 | PubMed |
| 40430429 | Structural Activity Relationship Analysis of New Diphenyl PFI-3 Analogues Targeting for the Treatment of Glioblastoma. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40430429 | PubMed |
| 38139302 | Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38139302 | PubMed |
| 37485377 | Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells. | iScience | 2023 | https://conductscience.org/library/papers/37485377 | PubMed |
Genes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36733367
GET https://conductscience.org/api/papers/v1/36733367/references?page=2